DBV Technologies S.A. (NASDAQ:DBVT - Free Report)'s stock is scheduled to reverse split on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, November 28th.
DBV Technologies Stock Down 2.2 %
Shares of DBV Technologies stock traded down $0.01 during trading hours on Wednesday, reaching $0.62. The company's stock had a trading volume of 72,309 shares, compared to its average volume of 231,567. DBV Technologies has a one year low of $0.50 and a one year high of $2.14. The stock's fifty day simple moving average is $0.74 and its two-hundred day simple moving average is $0.90.
Analysts Set New Price Targets
A number of research firms recently weighed in on DBVT. StockNews.com began coverage on shares of DBV Technologies in a research report on Wednesday, November 6th. They set a "hold" rating on the stock. HC Wainwright raised their price target on shares of DBV Technologies from $5.00 to $7.00 and gave the company a "buy" rating in a research report on Thursday, October 24th. Finally, JMP Securities reissued a "market outperform" rating and set a $5.00 price target on shares of DBV Technologies in a research report on Tuesday, September 24th.
Read Our Latest Analysis on DBV Technologies
Institutional Trading of DBV Technologies
A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. increased its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 6.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,568,909 shares of the company's stock after buying an additional 327,345 shares during the period. DBV Technologies comprises about 0.2% of Yiheng Capital Management L.P.'s holdings, making the stock its 15th biggest position. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the SEC. 71.74% of the stock is owned by institutional investors and hedge funds.
About DBV Technologies
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Articles
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
